A Phase IIa, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination With Venetoclax Plus Decitabine in Patients With AML Who Are Ineligible for Intensive Induction Therapy
Bio-Path Holdings, Inc. is conducting a Phase IIa open-label clinical trial to evaluate BP1001, a liposomal Grb2 antisense oligonucleotide, in combination with venetoclax and decitabine for patients with acute myeloid leukemia (AML) who are ineligible for intensive induction therapy. The trial aims to demonstrate improved efficacy over existing treatments, potentially positioning BP1001 as a novel therapeutic option in a market characterized by high unmet need and limited treatment options for this patient population. The combination therapy could enhance Bio-Path's competitive edge in the AML market, which is projected to grow due to increasing incidence rates and advancements in targeted therapies. Successful outcomes could lead to expedited regulatory pathways and partnerships with larger pharmaceutical companies for commercialization.
Indication: Acute Myeloid Leukemia (AML)
Modality: combination therapy
Target: Growth Factor Receptor-Bound Protein 2 (Grb2)
Sponsor: Bio-Path Holdings, Inc.
Source URL: ClinicalTrials.gov
Source updated: Mar 07, 2025
Ingested: Jun 19, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Growth Factor Receptor-Bound Protein 2 (Grb2)
View original source fields
Condition raw: Acute Myeloid Leukemia (AML)
Condition normalized: Acute Myeloid Leukemia (AML)
Modality raw: combination therapy
Modality normalized: combination therapy
Target raw: Growth Factor Receptor-Bound Protein 2 (Grb2)
Target normalized: Growth Factor Receptor-Bound Protein 2 (Grb2)